Merck Sharp & Dohme Limited

Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU
Telephone: +44 (0)1992 467 272
Fax: +44 (0)1992 479 292
Medical Information e-mail: medicalinformationuk@merck.com

Summary of Product Characteristics last updated on the eMC: 06/06/2011
SPC Marvelon

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 06/06/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
Date of revision of text on the SPC:   10-May-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.7 wording has been updated in line with standard terminology and now reads:

No observed effects.

Updated on 21/04/2009 and displayed until 06/06/2011
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Mar-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 9

Date of First Authorisation/Renewal of the Authorisation

04 November 1981/ 16 March 2009-04-08

 

 

 

Section 10

Date of Revision of the Text

March 2009

Updated on 20/03/2006 and displayed until 21/04/2009
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 30/09/2002 and displayed until 20/03/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 21/08/2001 and displayed until 30/09/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   ethinylestradiol
   desogestrel